I 
113TH CONGRESS 
2D SESSION 
H. R. 4746 
To amend the Public Health Service Act to establish a program of research 
regarding the risks posed by the presence of dioxin, synthetic fibers, 
chemical fragrances, and other components of feminine hygiene products. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 28, 2014 
Mrs. CAROLYN B. MALONEY of New York (for herself, Mr. FARR, and Ms. 
MOORE) introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act to establish a pro-
gram of research regarding the risks posed by the pres-
ence of dioxin, synthetic fibers, chemical fragrances, and 
other components of feminine hygiene products. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Robin Danielson Act 
of 2014’’. 
SEC. 2. FINDINGS. 
The Congress finds as follows: 
VerDate Mar 15 2010 
05:51 Jun 03, 2014
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4746.IH
H4746
jbell on DSK4SPTVN1PROD with BILLS
(1) Feminine hygiene products are widely used 
by women in the United States today, but there is 
not enough research on the components of these 
products. 
(2) Women may be exposed to substances in 
tampons and other menstrual products for as long 
as 60 years over the course of their reproductive 
lives. The average woman may use as many as 
16,800 tampons in her lifetime. A woman on meno-
pausal hormone therapy may use as many as 24,360 
tampons in her lifetime. 
(3) Trace amounts of dioxins can be found in 
tampons or other feminine hygiene products. The 
Environmental Protection Agency and the Inter-
national Agency for Research on Cancer, an arm of 
the World Health Organization, have concluded that 
dioxins are a probable human carcinogen (cancer- 
causing agent). 
(4) The Food and Drug Administration (re-
ferred to in this section as the ‘‘FDA’’) has histori-
cally relied on data provided by manufacturers of 
feminine hygiene products in determining product 
safety. 
(5) Although the FDA currently requires tam-
pon manufacturers to routinely monitor dioxin levels 
VerDate Mar 15 2010 
05:51 Jun 03, 2014
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4746.IH
H4746
jbell on DSK4SPTVN1PROD with BILLS
in raw materials and finished tampons, this informa-
tion is not readily available to the public. The FDA 
should consider whether to expand regulation to in-
clude other types of feminine hygiene products and 
a broader list of contaminants. 
SEC. 3. RESEARCH ON DIOXIN AND OTHER POTENTIALLY 
HARMFUL COMPONENTS OF FEMININE HY-
GIENE PRODUCTS. 
Part F of title IV of the Public Health Service Act 
(42 U.S.C. 287d et seq.) is amended by adding at the end 
the following section: 
‘‘SEC. 486C. RESEARCH ON DIOXIN AND OTHER POTEN-
TIALLY HARMFUL COMPONENTS OF FEMI-
NINE HYGIENE PRODUCTS. 
‘‘(a) RESEARCH.— 
‘‘(1) IN GENERAL.—The Director of NIH, in 
collaboration with the Director of the Office, shall 
provide for the conduct or support of research to de-
termine the extent to which the presence of dioxins, 
synthetic fibers, chlorine, and other components, in-
cluding contaminants and substances used as fra-
grances, in tampons and other feminine hygiene 
products— 
‘‘(A) poses any risks to the health of 
women who use the products, including risks re-
VerDate Mar 15 2010 
05:51 Jun 03, 2014
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4746.IH
H4746
jbell on DSK4SPTVN1PROD with BILLS
lating to cervical cancer, endometriosis, infer-
tility, ovarian cancer, breast cancer, immune 
system deficiencies, pelvic inflammatory disease, 
toxic shock syndrome, and bacterial and yeast 
infections; and 
‘‘(B) poses any risks to the health of chil-
dren of women who used such products during 
or before the pregnancies involved, including 
risks relating to fetal and childhood develop-
ment. 
‘‘(2) REQUIREMENT
REGARDING
DATA
FROM 
MANUFACTURERS.—Research under paragraph (1) 
shall include research to confirm the data on tam-
pons and other feminine hygiene products submitted 
to the Commissioner of Food and Drugs by manu-
facturers of such products. 
‘‘(3) DEFINITION.—For purposes of paragraph 
(1), the term ‘feminine hygiene products’ means 
tampons, pads, liners, cups, sponges, and similar 
products used by women with respect to menstrua-
tion or other genital-tract secretions. 
‘‘(b) REPORTS.—Reports on the results of research 
under subsection (a) shall be periodically submitted to the 
Congress, the Commissioner of Food and Drugs, the Ad-
ministrator of the Environmental Protection Agency, and 
VerDate Mar 15 2010 
05:51 Jun 03, 2014
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H4746.IH
H4746
jbell on DSK4SPTVN1PROD with BILLS
the Chairman of the Consumer Product Safety Commis-
sion. Such reports shall be made available to the public 
through the data system and clearinghouse program es-
tablished under section 486A, or through other appro-
priate means. 
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there are authorized 
to be appropriated such sums as may be necessary for 
each of the fiscal years 2015 through 2019.’’. 
Æ 
VerDate Mar 15 2010 
05:51 Jun 03, 2014
Jkt 039200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H4746.IH
H4746
jbell on DSK4SPTVN1PROD with BILLS